Clinical Trial Applications - Approved: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Date Approved | |
|---|---|---|---|---|---|
51. |
ECCT/09/06/02 | A Randomized Trial to Evaluate the Effectiveness of Antiretroviral Therapy plus HIV Primary Care versus HIV Primary Care Alone to Prevent the Sexual Transmission of HIV-1 In Serodiscordant Couples |
Principal Investigator(s) 1. Lisa Ann Mills Site(s) in Kenya Kisumu, Kenya |
05-07-2012 |
View |
52. |
ECCT/20/07/02 | RV 460 HIV Vaccine Trial A Randomized, Double-Blind Phase 1 Trial to Evaluate the Safety and Immunogenicity of Priming with Env-C Plasmid DNA Vaccine Alone, with Different Adjuvants, or with an Adjuvanted HIV Env gp145 C.6980 Protein Vaccine and Boosting with the Adjuvanted HIV Env gp145 C.6980 Protein Vaccine with or without the Env-C Plasmid DNA Vaccine in Healthy HIV Uninfected Adults in Kenya |
Principal Investigator(s) 1. Josphat Kosgei Site(s) in Kenya KEMRI/US MRDA-A/K, KERICHO |
19-10-2020 |
View |
53. |
ECCT/15/11/05 | FALCI Study A Randomized, Double-blind, Phase IIb Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of a Single Dose Regimen of Ferroquine (FQ) with Artefenomel (OZ439) in Adults and Children with Uncomplicated Plasmodium falciparum Malaria. |
Principal Investigator(s) 1. Grace Kiringa Kaguthi Site(s) in Kenya 1. KEMRI Center for Respiratory Diseases Research (Siaya county) 2. KEMRI Walter Reed Kombewa (Kisumu county) 3. KEMRI Kisumu (Kisumu county) |
01-02-2016 |
View |
54. |
ECCT/22/05/01 | VICTORION-2 PREVENT A randomized, double-blind, placebo-controlled, multicenter trial, assessing the impact of inclisiran on major adverse cardiovascular events in participants with established cardiovascular disease |
Principal Investigator(s) 1. Anthony Gikonyo 2. ELIJAH SAMMY NYAINDA OGOLA Site(s) in Kenya 1. The Karen Hospital (Nairobi City county) 2. Centre for research in Therapeutic Sciences (CREATES (Nairobi City county) |
05-10-2022 |
View |
55. |
ECCT/20/01/01 | LEVERAGING THE DEPRESSION AND PRIMARY-CARE PARTNERSHIP FOR EFFECTIVENESS-IMPLEMENTATION RESEARCH A SEQUENTIAL, MULTIPLE ASSIGNMENT RANDOMIZED TRIAL (SMART) FOR NON-SPECIALIST TREATMENT OF COMMON MENTAL DISORDERS IN KENYA: LEVERAGING THE DEPRESSION AND PRIMARY-CARE PARTNERSHIP FOR EFFECTIVENESS-IMPLEMENTATION RESEARCH (DAPPER) PROJECT (SMART-DAPPER) |
Principal Investigator(s) 1. Anne Muthoni Mathai 2. Susan Meffert Site(s) in Kenya Kisumu County Hospital |
31-03-2020 |
View |
56. |
ECCT/16/05/01 | A5338 A5338 An Open-Label, Non-Randomized Study of Pharmacokinetic Interactions Among Depot Medroxyprogesterone Acetate (DMPA), Rifampicin (RIF), and Efavirenz (EFV) in Women Co-Infected with Human Immunodeficiency Virus (HIV) and Tuberculosis (TB) |
Principal Investigator(s) 1. David Schnabel Site(s) in Kenya KISUMU CRS |
28-07-2016 |
View |
57. |
ECCT/22/02/01 | An Open label Inclacumab study An Open-Label Extension Study to Evaluate the Long-Term Safety of Inclacumab Administered to Participants with Sickle Cell Disease Who Have Participated in an Inclacumab Clinical Trial |
Principal Investigator(s) 1. Bernhards Ragama Ogutu 2. Fredrick Asirwa Chite 3. Videlis N nduba 4. Prof Jessie N Githanga Site(s) in Kenya 1. Strathmore University Medical Centre (Nairobi City county) 2. International Cancer Institute (ICI)-Eldorate (Uasin Gishu county) 3. KEMRI/CRDR (Nairobi City county) 4. KEMRI Siaya Clinical Research Annex (Siaya county) 5. Gertrude’s Children’s Hospital. (Nairobi City county) 6. Strathmore University Medical Centre (Nairobi City county) |
16-05-2022 |
View |
58. |
ECCT/22/04/01 | GBT Open Label inclacumab Ph3 An Open-Label Extension Study to Evaluate the Long-Term Safety of Inclacumab Administered to Participants with Sickle Cell Disease Who Have Participated in an Inclacumab Clinical Trial |
Principal Investigator(s) 1. Bernhards Ragama Ogutu 2. Fredrick Asirwa Chite 3. Prof Jessie N Githanga 4. Videlis N Nduba Site(s) in Kenya 1. Strathmore University Medical Centre (Nairobi City county) 2. International Cancer Institute (ICI)-Eldoret (Uasin Gishu county) 3. KEMRI/CRDR (Nairobi City county) 4. KEMRI Siaya Clinical Research Annex (Siaya county) 5. Gertrude’s Children’s Hospital. (Nairobi City county) |
31-05-2022 |
View |
59. |
ECCT/22/08/01 | GBT Open Label inclacumab Ph3 An Open-Label Extension Study to Evaluate the Long-Term Safety of Inclacumab Administered to Participants with Sickle Cell Disease Who Have Participated in an Inclacumab Clinical Trial |
Principal Investigator(s) 1. Prof Jessie N Githanga 2. Bernhards Ragama Ogutu 3. Fredrick Asirwa Chite 4. Videlis N Nduba Site(s) in Kenya 1. Gertrude’s Children’s Hospital (Nairobi City county) 2. Strathmore University Medical Centre (Nairobi City county) 3. International Cancer Institute (ICI)-Eldoret (Uasin Gishu county) 4. KEMRI/CRDR (Nairobi City county) 5. KEMRI Siaya Clinical Research Annex (Siaya county) |
19-10-2022 |
View |
60. |
ECCT/25/05/04 | Floral roll over study An open-label, multi-centre, rollover study to characterise long-term safety and efficacy of etavopivat in adults, adolescents and children who have sickle cell disease or thalassaemia and have completed a treatment period in an etavopivat study. |
Principal Investigator(s) 1. Bernhard Ogutu Site(s) in Kenya 1. KEMRI Kondele Children\'s Hospital (Kisumu county) 2. Center for Research in Therapeutic Sciences (CREATES) (Kisumu county) 3. Gertrudes Childrens Hospital (Nairobi City county) 4. KEMRI Siaya Clinical Research Annex (Siaya county) 5. KEMRI/ WRAIR-Africa, Kombewa Clinical Research Center (Kisumu county) 6. KEMRI WALTER REED KERICHO (Kericho county) 7. KEMRI/ WRAIR-Africa, Kombewa Clinical Research Center (Kisumu county) |
09-12-2025 |
View |